Bio-Techne FY2025 10-K: 5% Revenue Growth Offset by One-Time Charges and Impairments

What happened

Bio-Techne reported $1.22 billion in consolidated net sales for fiscal 2025, representing 5% growth versus the prior year, all of which was organic. The Protein Sciences segment grew 5% after declining 2% in fiscal 2024, driven by strong proteomic analytical solutions, cell therapy performance, and commercial execution. Diagnostics and Spatial Biology grew 6%, supported by broad-based molecular diagnostics performance and Lunaphore's organic growth, though this decelerated from the prior year's 12% growth which included acquisition contributions. Consolidated gross margin compressed to 64.8% from 66.4% in the prior year, impacted by reinstatement of incentive accruals and unfavorable product mix. On an adjusted basis, gross margin was 70.4% versus 71.0% in fiscal 2024. GAAP net earnings declined 56% due to several one-time items: an $80.5 million impairment charge on held-for-sale assets, a $41.8 million non-recurring arbitration award, and $28.2 million in restructuring and restructuring-related costs. Excluding these items and other adjustments, adjusted net earnings increased 8% to $306.5 million, reflecting favorable volume leverage within Protein Sciences. Operating cash flow decreased to $287.6 million from $299.0 million in the prior year, primarily due to timing of payments on operating assets and liabilities. The Company drew $313 million under its $1 billion revolving credit facility as of August 16, 2025. The effective tax rate increased to 25.5% from 9.5% in the prior year, driven by fewer stock option exercises and lower share-based compensation excess tax benefits ($4.5 million in fiscal 2025 versus $18.4 million in fiscal 2024).

Why it matters for investors

The return to mid-single-digit organic growth in both segments indicates Bio-Techne is emerging from the post-pandemic demand normalization that weighed on fiscal 2024 results. The Protein Sciences segment's recovery to 5% growth after a 2% decline suggests stabilization in life sciences research spending, a critical end market. However, gross margin compression—both reported and adjusted—signals pressure from product mix shifts and the reinstatement of incentive compensation, which may reflect management's acknowledgment of improved execution but also ongoing cost structure challenges. The elevated restructuring activity ($28.2 million versus $12.2 million in fiscal 2024) and dual asset impairments totaling $103.5 million over two fiscal years suggest portfolio rationalization is underway, with the Company divesting underperforming or non-core assets including the announced sale of Exosome Diagnostics for $15 million. The mandatory Wilson Wolf acquisition obligation—approximately $1 billion due by December 2027—represents a significant future use of capital that will test the Company's balance sheet flexibility, particularly given current debt of $346 million and the potential for earlier triggering if financial milestones are met. The sharp increase in share repurchases to $275.7 million from $80.0 million suggests management is using excess cash for buybacks while deleveraging modestly, but the looming Wilson Wolf obligation may constrain this activity in future periods. The tax rate normalization to 25.5% indicates the prior year's 9.5% rate was artificially low due to discrete benefits, and investors should model a mid-20s tax rate going forward.

Key highlights

Bio-Techne operates in two segments: Protein Sciences (71% of revenue), which develops biological reagents and proteomic analytical tools, and Diagnostics and Spatial Biology (29% of revenue), which produces diagnostic assays, spatial genomic tools, and molecular diagnostics. The Company generates approximately 44% of revenue from outside the United States and faces exposure to foreign currency fluctuations, tariffs, and international regulatory changes including the EU IVDR requirements. Capital allocation during fiscal 2025 included $50.4 million in dividends, $275.7 million in share repurchases, $31.0 million in capital expenditures, and a $15.0 million investment in Spear Bio. The Company maintains a $1 billion revolving credit facility with $654 million of unutilized availability as of June 30, 2025. Goodwill of $980.9 million represents 38% of total assets, reflecting the Company's active M&A strategy. Management uses adjusted financial metrics excluding stock-based compensation, acquisition-related costs, amortization, restructuring charges, and certain litigation costs to evaluate performance.

Management commentary

Management stated that fiscal 2025 organic revenue growth was 'primarily driven by strong commercial execution in our Protein Sciences segment,' with 'strong proteomic analytical solutions and cell therapy performance' as key contributors. For Diagnostics and Spatial Biology, growth was attributed to 'broad based molecular diagnostics performance and Lunaphore's organic growth.' Management acknowledged that consolidated gross margin in fiscal 2025 'was impacted by the reinstatement of incentive accruals and product mix.' The Company disclosed it 'expects to be able to meet its cash and working capital requirements for operations, facility expansion, capital additions, and cash dividends for the foreseeable future, and at least the next 12 months, through currently available funds, including funds available through our line-of-credit and cash generated from operations,' though noting that 'future acquisition strategies may or may not require additional borrowings.' Regarding Wilson Wolf, management stated the Company 'will acquire the remaining ownership no later than the end of calendar year 2027' with a 'second option payment of approximately $1 billion plus potential contingent consideration forecasted to occur between fiscal 2026 and fiscal 2028.'

What to watch next

Investors should monitor:

• Protein Sciences segment growth sustainability and whether the 5% fiscal 2025 growth rate can be maintained as life sciences research spending trends evolve, particularly given exposure to pharmaceutical and biotech R&D budgets.

• Gross margin trajectory in both segments, particularly whether product mix headwinds and reinstated incentive accruals continue to compress profitability or if favorable volume leverage can offset these pressures.

• Timing and structure of the mandatory Wilson Wolf acquisition, including whether financial milestones are met that accelerate the transaction before December 2027 and the impact on leverage and capital allocation flexibility.

• Success of portfolio rationalization efforts, including completion of the Exosome Diagnostics divestiture announced for first quarter fiscal 2026 and whether additional held-for-sale classifications or impairments emerge.

• Impact of evolving tariff policies and trade tensions between the U.S. and China, given the Company generates 44% of revenue outside the U.S. and faces increased costs from tariffs on imported supplies and components that may require surcharges or pricing actions.

This summary is based solely on excerpts from the company's Form 10-K filing.